Cartesian Therapeutics Inc. (RNAC) — Cash Flow Quality Index
Cartesian Therapeutics Inc. (RNAC) has a Cash Flow Quality Index of -1.10x as of June 2025. Operating cash flow of $-17.52 Million is below net income of $15.89 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore RNAC long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cartesian Therapeutics Inc. Cash Flow Quality Index (2022–2022)
Historical Cash Flow Quality Index for Cartesian Therapeutics Inc. across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Cartesian Therapeutics Inc. (RNAC) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Cartesian Therapeutics Inc. (2022–2022)
Year-by-year earnings quality comparison for Cartesian Therapeutics Inc.. For live market cap and the full company financial profile, see Cartesian Therapeutics Inc. (RNAC) market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | -0.89x | $-31.63 Million | $35.38 Million | — |